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Abstract
Background: To investigate the association between severity of acute kidney injury (AKI) and outcome, systemic
inflammatory phenotype and HLA genotype in severe sepsis.
Methodology/Principal Findings: Prospective multicenter observational study done in 4 intensive care units in two
university hospitals. Severe sepsis and septic shock patients with at least 2 organ failures based on the SOFA score were
classified: 1) "no AKI", 2) "mild AKI" (grouping stage 1 and 2 of AKIN score) and 3) "severe AKI" (stage 3 of AKIN score).
Sequential measurements: The vasopressor dependency index (VDI; dose and types of drugs) to evaluate the association
between hemodynamic status and the development of early AKI; plasma levels of IL-10, macrophage migration inhibitory
factor (MIF), IL-6 and HLA-DR monocyte expression. Genotyping of the 13 HLA-DRB1 alleles with deduction of presence of
HLA-DRB3, -DRB4 and -DRB5 genes. We used multivariate analysis with competitive risk model to study associations. Overall,
176 study patients (146 with septic shock) were classified from AKIN score as "no AKI" (n=43), "mild AKI" (n=74) or "severe
AKI" (n=59). The VDI did not differ between groups of AKI. After adjustment, "mild and severe AKI" were an independent
risk factor for mortality (HR 2.42 95%CI[1.01-5.83], p=0.048 and HR 1.99 95%CI[1.30-3.03], p=0.001 respectively). "Severe
AKI" had higher levels of plasma IL-10, MIF and IL-6 compared to ‘‘no AKI’’ and mild AKI (p,0.05 for each), with no difference
in mHLA-DR at day 0. HLA-DRB genotyping showed a significantly lower proportion of 4 HLA-DRB alleles among patients
requiring renal replacement therapy (RRT) (58%) than in patients with severe AKI who did not receive RRT (84%) (p=0.004).
Conclusions: AKI severity is independently associated with mortality and plasma IL-10, MIF or IL-6 levels. Presence of 4
alleles of HLA-DRB in severe AKI patients seems associated with a lower need of RRT.
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Introduction
Acute kidney injury (AKI) is common in intensive care patients
and associated with a worse prognosis [1,2,3]. Relatively few
studies have reported the potential difference between outcome
association and AKI severity grading in severe sepsis or septic
shock. The association between AKI and outcome is still poorly
understood and is considered related to hypoperfusion [4,5].
Several arguments challenge this view: not all septic shock patients
develop AKI despite similar hypotension and hemodynamic
resuscitation; fresh human renal biopsies after death fail to show
important ischemic lesions; biopsies show frequent microvessel
thrombosis, infiltration by immune cells, and apoptosis [6]; the
recently introduced biomarker neutrophil gelatinase-associated
lipocalin (NGAL) a metallo-protein from neutrophils, is a good
predictor of severe AKI [7] with a large lipocalin gene expression
during post-ischemic reperfusion [8]. All of these observations
suggest an important role of ‘‘renal immune toxicity.’’ Among
these non hemodynamic factors, the intensity of the systemic
inflammatory response and genetic factors are reasonable candi-
dates during severe sepsis. In this multicentric study, we
sequentially looked at the level of plasma MIF and IL-6 as pro-
and IL-10 as anti-inflammatory cytokine to assess inflammatory
response. In addition to cytokine plasma levels, monocyte human
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cellular innate functional test. The focus on major histocompat-
ibility complex (MHC) class II expression came from the well
demonstrated rapid (hours) and deep downregulation of HLA-DR
in circulating monocytes during severe sepsis [9,10,11]. In
addition, MHC class II expression protein especially HLA-DR
expression is constitutive to peritubular and glomerular capillary
endothelium [12,13]. In acute inflammation, such as acute renal
rejection or glomerulonephritis [13], HLA class II protein
expression was induced on proximal tubular cells [12] or after
stimulation by interferon c [14]. The selective expression of HLA-
DR in kidney microvasculature indicates an unusual regulation of
class II that may contribute to the kidney response to foreign
antigenes. The HLA-DRB genes, highly polymorphic genes of
MHC class II, were chosen to study the HLA-DR genotype.
Because these genes are associated together in linkage desequili-
brium, we expected this approach would detect a haplotype-
phenotype association with greater probability.
Materials and Methods
Ethics
This multi-centre study was approved by the AP-HP Cochin
Hospital Ethics Committee (# CCPPRB 2061), which was valid
for all AP-HP hospitals. Written informed consent was obtained
for each patient from the patient himself or next of keen.
Patients
This study involved patients from 4 Intensive Care Units in
Paris, France, including 2 medical and 2 surgical ICUs. Patients
fulfilling the criteria of severe sepsis or septic shock defined
according to the ACCP/SCCM consensus conference [15] and
having at least two organ failures defined by the SOFA (sequential
organ failure assessment) score (value .1 for each organ failure
were considered) [16] were included between January 2004 and
December 2005. Patients with chronic renal failure were excluded
(Figure 1). Epidemiological characteristics and common past
medical events were collected. Use of vasopressors, inotropes,
hydrocortisone, activated protein C, insulin, fluid loading, and
renal replacement therapy (RRT) were recorded. Mortality was
assessed at the 28
th day after enrolment. Patients who died during
the first 48 hrs were excluded from this study, considering the
time-evolution too short to meet the criteria for AKI definition
(Figure 1) [17].
Since the present study was designed before the publication of
the RIFLE and AKIN scores [17,18], patients were classified on
the basis of recalculated AKIN score [16] [19]. The concordance
between the SOFAkidney and AKIN score classifications was good
(91% of patients were identically classified) (Table S1). We report
only the results based on AKIN score. The worst value of these
renal classifications within the first forty-eight hours (day 2) was
recorded. Since the AKIN score is based on creatinine increases
from baseline and, in most cases the baseline creatinine level was
unknown, it was calculated with the Modified Diet in Renal
Disease formula based on a creatinine clearance of 75 ml/min
[18]. Patients were classified in three groups: 1) patients without
early AKI (serum creatinine#110 mmol/L; UO .0.5 ml/kg/hr
i.e. AKIN 0), 2) patients with mild AKI (AKIN 1 or 2) and 3)
patients with severe AKI (AKIN 3). According to the original
recommendation [18] for RRT, individuals who receive RRT
were considered to have met the criteria for stage 3. Organ failures
were classified accordingly to their SOFA score. An organ was
considered failing when SOFA score for this organ was of 1 or
over 1. To assess the role of shock in the development of early
AKI, we stratified patients according to cardiovascular failure
using the vasopressor dependency index (VDI) which takes into
consideration the vasopressor dose and the mean arterial pressure
(MAP). The vasopressor dependency index was calculated as the
ratio of catecholamine index to the MAP [20], the catecholamine
index being calculated as follows: (dopamine dose61)+(dobuta-
mine dose61)+(adrenaline dose6100)+(noradrenaline do-
se6100)+(phenylephrine dose6100), with all doses expressed as
mg/kg/min.
Description of Procedures or Investigations Undertaken
Inflammatory parameters. Blood samples were collected at
day 0, day 1, day 2 for measurements of monocyte HLA-DR
expression and plasma cytokines.
Monocyte HLA-DR expression was measured by flow cytom-
etry with a FACScan instrument (Becton Dickinson, San Jose, CA)
and Cellquest software (Becton Dickinson). Double color staining
was performed on whole blood with isotype control antibodies
(Simultest control), anti CD14 antibodies attached to fluorescein
isothiocyanate (clone MwP9), and anti HLA-DR antibodies
attached to phycoerythrin (clone L243), according to the
manufacturer recommendations (Becton Dickinson). The anti
HLA-DR antibody was raised against the a-subunit of the HLA-
DR receptor [21]. The mean fluorescence intensity displayed by
anti HLA-DR attached to phycoerythrin was analyzed in the
monocyte population, gated as a cell population with appropriate
light scattering properties and with CD14 expression. Expression
of HLA-DR was quantified by the number of antibodies bound
per cell (AB/C) (QuantibriteH, Becton Dickinson) converting the
classic mean fluorescence intensity (MFI) after calibration to
compare the results obtained with different flowcytometers. The
regression slope of correlation between MFI and the estimated
AB/C never varied over time and ranged between 0.999 and 1.
Plasma IL-10 and MIF levels were determined by an
immunoenzymatic method (ELISA): plasma IL-10 using a
PharMingen kit (optEIA
TM set, BD PharMingen, San Diego,
CA) according to the manufacturer’s recommendations. Plasma
MIF was measured using monoclonal anti-human MIF and
biotinylated anti-human MIF antibodies, with recombinant
human MIF (R&D systems, Abingdon, Oxon, UK). IL-6 plasma
levels were measured by Electro-chemiluminescence immunoassay
(ECLIA) (Roche Diagnostics) using automated Cobas e601 (Roche
Diagnostics).
Standard samples ranged from 7.8 to 500 pg/ml for IL-10 and
from 31.25 to 2000 pg/ml for MIF. Detection thresholds were
3.5263.39 pg/ml for IL-10, 13.3666.02 pg/ml for MIF and
1.5 pg/ml for IL-6. Normal values in the laboratory were
0.7160.52 pg/ml for plasma IL-10, 404.286681.60 pg/ml for
MIF and below 7 pg/ml for IL-6.
HLA-DRB1 genotyping. The heterodimeric protein receptor
HLA-DR [22] consists in one a- and one b-chain, respectively
encoded by one a-gene and four functional b-genes, called HLA-
DRB1, -DRB3, -DRB4, and -DRB5. HLA-DRB1 is constitutively
always present with more than 100 different alleles. The individual
HLA-DRB haplotypes correspond to the presence or not of
specific combination between HLA-DRB1 gene and one other
DRB genes on each chromosome 6. The genotyping included the
detection of the HLA-DRB1 alleles, which allowed to define the
different haplotypes [23]. The genotypes HLA-DRB3, -DRB4,
and -DRB5 were then deducted from their specific associations
(linkage dsequilibrium) with the HLA-DRB1 alleles: presence of
HLA-DRB3 is linked to the following HLA-DRBB1 alleles: HLA-
DRB1*03, DRB1*11, DRB1*12, DRB1*13, or DRB1*14; HLA-
DRB4 is linked to: HLA-DRB1*04, DRB1*07, or DRB1*09; and
AKI: Hemodynamic, Inflammation and HLA Genotyping
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Combination of HLA-DRB genes in an individual genome varies
from two genes (one HLA-DRB1 genes on each chromosome 6) to
four genes, when the two HLA-DRB1 genes are in linkage
disequilibrium with a second HLA-DRB gene. Homozygosity was
defined when in addition to both HLA-DRB1 genes, the linkage
disequilibrium was with HLA-DRB3 (B3/B3), HLA-DRB4 (B4/
B4), or HLA-DRB5 (B5/B5). For HLA-DRB1 typing, the medium
resolution genotyping was performed using polymerase chain
reaction (PCR) sequence using a specific oligonucleotide reverse
dot blot kits (InnoLipa HLA-DRB1 kit, Innogenetics, Zwijndrecht,
Belgium).
Statistical Analysis
Results are expressed as mean (SD) or median (25
th to 75
th
percentiles) while categorical variables were expressed as count
and percentage. Comparisons among the three groups (i.e. no
AKI, mild AKI and severe AKI respectively) were performed
with Kruskal-Wallis test and Chi-square test for continuous and
categorical variables respectively. Patients with no AKI and mild
AKI were pooled and compared to patients with severe AKI
using the Mann-Whitney for continuous variables and Chi-
square tests for categorical variables. Cumulative incidence of all-
cause in-hospital mortality over time was estimated, considering
being alive at discharge as a competing event. The length of stay
was computed from 48 hours after ICU admission till the date of
death, discharge or transfer. The association of AKI with survival
was estimated without and with adjustment on prognostics
covariates (namely age, gender, comorbidities (diabetes and
cancer) and the SOFA score with exclusion of the renal item,
SOFA-II). Logistic regression was used to determine a set of
variables independently associated with severe AKI. Variables
included in the model were chosen based on their clinical
relevance among variables associated with severe AKI at a 0.05
level. The model selection used was a stepwise backward-forward
procedure. Discriminative ability of the final model was
evaluated by the c- index (identical to the area under the
receiver operating characteristics [ROC] curve). Two-way
ANOVA analysis for repeated measurement was used to
compare variation of different biological values between severe
AKI and no or mild AKI and between the two types of
genotypes (two or three versus four alleles, see below for details).
p,0.05 was considered as statistically significant. All analyses
were performed using R 2.6.2 statistical software (The R
Foundation for Statistical Computing, Vienna, Austria).
Genetic analysis. Allelic frequencies of HLA alleles were
calculated by gene counting, and compared between groups either
by chi-square test (with Yates correction if needed) or Fisher exact
test using 262 contingency tables. The significance was set to pc
,0.05. Healthy Caucasians (n=172) constituted the reference
population in the lab, HAYEM reference panel [24].
Figure 1. Flowchart of the enrolled septic patients with different AKI severity and outcome.
doi:10.1371/journal.pone.0035838.g001
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Patients
The study flow diagram is shown in Figure 1. Of the 221
screened patients, 20 were not included because of chronic renal
failure and 23 additional patients were excluded because of early
death (within 48 hours) before the criteria of early AKI could be
met. Two additional patients were not included because of brain
death. The majority of patients were caucasian (94%) and
relatively few patients fit with extreme weights (median weight
71 kg, IQ (60–82)). Only 2 patients free of AKI after 48 hrs later
developed AKI. Age and gender did not differ between patients
with and without AKI (Table 1). Patients with AKI were less likely
to have COPD or chronic respiratory insufficiency compared to
patients with no AKI. Occurrence of other organ failure did not
differ between groups on inclusion. However, patients with severe
AKI had higher severity of illness on admission (for both SAPS II
and SOFA scores) compared to the no AKI and mild AKI groups.
This was also observed for mild AKI compared to no AKI
(Table 1). The site of infection was more frequently the lung in no
AKI group than in others (Table 2). Pathogens responsible for
sepsis did not differ between groups (Table 2).
During the first 48 hours, 30 patients had severe sepsis and 146
were in shock and 36 patients (28% of AKI patients) necessitated
renal replacement therapy (RRT) within the first week. The
severity of cardiovascular failure expressed as the VDI did not
significantly differ between sub-groups of AKI (p value of Kruskal-
Wallis 0.63) (Table S2). Patients with severe AKI were more likely
to receive hydrocortisone (81.5%) in comparison with mild AKI
and no AKI (vs. 51% and 51% respectively) (p,0.00059, Table 3).
Patients with severe AKI also received recombinant activated
protein C (APC) more often than did patients with mild AKI
(18.5% vs. 4.1%) (p,0.00063, Table 3).
Relation between AKI Severity and Outcome
Over the first 48 hours, patients with mild and severe AKI had
more frequent non-renal organ failures than "no AKI" group as
illustrated by higher SAPSII (p=0.0073 and p,0.0001 respec-
tively) and SOFA (p,0.0001 for both) scores. ‘‘Severe AKI’’
patients showed similar differences when compared with "mild
AKI" for both scores (p,0.0001). Among organ failure items,
"severe AKI" had higher serum bilirubin values than "No AKI"
(p=0.00044) and "mild AKI" (p=0.074), a lower prothrombin
values than "no AKI" (p=0.0029) and "mild AKI" (p=0.0024),
a lower platelet count than "no AKI" (p=0.0038) and a lower
mean arterial pressure than "no AKI" (p=0.00011) and "mild
AKI (p=0.00053) (Tables 1 and 3). The delay between the 1
st
and the 2
nd organ failure averaged 18 hrs and AKI was the first
OF in 75 patients (43%) preceding cardiovascular failure. Two
patients without AKI later developed severe AKI and 4 mild
AKI patients later developed severe AKI.
Patients with "severe AKI" had a significantly higher mortality
rate at day 28 (40.7%) compared to patients with mild AKI (26%)
or no AKI (12%) (p=0.001) (Figure 2a). The multivariate analysis
(Figure 2b) using competitive risks model as an independent factor
of mortality after adjusting for age, gender, presence of diabetes
and cancer and the SOFA score, excluding the renal item showed
differences for "severe AKI" versus "no AKI" or "mild" AKI
(Hazard Ratio (HR) 2.27 CI 1.30-3.97; p=0.004). In absence of
adjustment, "mild AKI" versus no AKI (HR 2.42 CI 1.01-5.83;
p=0.048) were significant and "severe AKI" versus "mild AKI"
was closed to the significance (HR 1.74 CI 0.97-3.12; p=0.061).
Table 1. Clinical characteristics of patients at inclusion.
No AKI (n=47) Mild AKI (n=75) Severe AKI (n=54)p p1 p2 p3
Age, years 60.1 (15.1) 61 (15.7) 63.3 (15.5) 0.61
Sexe – male(%) 30 (63.8) 47 (63.5) 34 (63) 1
Comorbidities, n(%)
- cardio-vascular 22 (46.8) 30 (40.5) 26 (48.1) 0.69
- respiratory 9 (19.1) 6 (8.1) 2 (3.7) 0.032 0.092 0.022 0.47
- Diabete 4 (8.5) 16 (21.6) 8 (14.8) 0.16
- Liver cirrhosis 0 (0) 4 (5.4) 3 (5.6) 0.29
- Cancer 4 (8.5) 15 (20.3) 10 (18.5) 0.23
- Immnosuppression 7 (14.9) 4 (5.4) 4 (7.4) 0.21
Surgical sepsis, n(%) 8 (17) 20 (27) 12 (22.2) 0.47
Secondary infection, n(%) 14 (29.8) 26 (35.1) 13 (24.1) 0.4
SOFA score 5.4 (2.1) 7.3 (2.8) 10 (3) ,0.0001 ,0.0001 ,0.0001 ,0.0001
SAPS II 37.8 (12.4) 44.2 (13) 55.3 (13.7) ,0.0001 0.0073 ,0.0001 ,0.0001
Organ failures 2.6 (0.6) 3.1 (1) 3.6 (1.1) ,0.0001 0.0022 ,0.0001 0.038
Organ failures, n(%)
- Cardio-vascular 43 (91.5) 67 (90.5) 49 (90.7) 1
- Hematologic 17 (36.2) 26 (35.1) 24 (44.4) 0.53
- Neurologic 14 (29.8) 22 (29.7) 17 (31.5) 0.98
- Hepatic 4 (8.5) 13 (17.6) 12 (22.2) 0.17
- Pulmonary 32 (68.1) 40 (54.1) 39 (72.2) 0.083
p; comparison between the 3 groups, no AKI, mild AKI and severe AKI. When significant: p1, comparison between no AKI and mild AKI; p2, between no AKI and severe
AKI; p3, between mild AKI and severe AKI with a Mann-Whitney –test or Chi2-test. Results are expressed in median (IQR).
doi:10.1371/journal.pone.0035838.t001
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"mild" and "severe" AKI included the following variables: SOFA
score, number of organ dysfunctions, mechanical ventilation, fluid
balance, PT, lactate, norepinephrine infusion, dobutamine infu-
sion. For "mild" AKI, SOFA score at admission (OR [95% CI]
=1.30 [1.10–1.53] for an increase of 1 unit, p=0.002) and the
number of organ failure at admission (OR [95% CI] =1.05
[1.00–1.09] for an increase of 1 organ failure, p=0.034) were
found to be independently associated. For "severe" AKI, only
SOFA score at admission (OR [95% CI] =1.64 [1.41–1.92] for
Table 2. Description of initial infection.
No AKI (n=47) Mild AKI (n=75) Severe AKI (n=54) p p1 p2 p3
Origin of infection n(%)
- Pneumonia 34 (72.3) 38 (51.4) 28 (51.9) 0.047 0.024 0.042 1
- Abdomen 8 (17) 15 (20.3) 13 (24.1) 0.72
- Central nervous system 2 (4.3) 2 (2.7) 1 (1.9) 0.73
- Urinary tract 0 (0) 10 (13.6) 6 (10.2) 0.29
- Skin and soft tissues 1 (2.1) 4 (5.4) 6 (11.1) 0.2
- Blood stream infection 2 (4.3) 6 (8.1) 0 (0) 0.06
Pathogens, n(%)
-Gram-negative bacteria 9 (26.5) 22 (37.9) 12 (33.3) 0.55
- Gram-positive bacteria 1 (2.9) 0 (0) 0 (0) 0.27
- Polymicrobial sepsis 13 (38.2) 16 (27.6) 14 (38.9) 0.42
- Others 2 (5.9) 2 (3.4) 1 (2.8) 0.72
p; comparison between the 3 groups, no AKI, mild AKI and severe AKI. When significant: p1, comparison between no AKI and mild AKI, p2, between no AKI and severe
AKI, p3, between mild AKI and severe AKI with a Mann-Whitney –test or Chi2-test. Results are expressed in median (IQR).
doi:10.1371/journal.pone.0035838.t002
Table 3. Clinical and biological characteristics of patients over the first 48 hours after inclusion.
No AKI (n=47) Mild AKI (n=75) Severe AKI (n=54) p p1 p2 p3
Highest SOFA score 6 (2.3) 8.1 (2.8) 11.6 (3) ,0.0001 ,0.0001 ,0.0001 ,0.0001
Lowest MAP, mmHg 58.5 (12.4) 55.7 (11.8) 44.4 (18.3) 0.00011 0.27 0.00011 0.00053
Mechanical ventilation, n(%) 36 (76.6) 47 (63.5) 46 (85.2) 0.02 0.16 0.31 0.0087
Lowest PaO2/FiO2 ratio 292 (118) 319(135.6) 277 (150.4) 0.083
Highest temperature, uC 38.5 (0.8) 38.7 (1) 38.5 (1.1) 0.2
Highest leukocyte,/mm
3 17.5 (10.7) 20 (12) 18.6 (12) 0.36
Lowest leukocyte,/mm
3 13.9 (8.6) 15.9 (10.6) 14.4 (10.1) 0.38
Highest glycemia, mmol/l 12.5 (4.3) 13.1 (6.1) 13.4 (5.2) 0.76
Lowest glycemia, mmol/l 7.1 (2.9) 7.6 (3) 7.5 (3.1) 0.25
Fluid balance ml 2183 (2497) 3023 (2620) 4368 (2653) ,0.0001 0.031 ,0.0001 0.0016
Received Colloids, n(%) 30 (63.8) 58 (78.4) 46 (86.8) 0.024 0.096 0.0097 0.25
Lowest platelet count, 10
3/mm
3 234 (144.4) 188 (117.4) 164 (115.3) 0.02 0.13 0.0038 0.17
Lowest prothrombin time, % 75.5 (22.2) 70.2 (18.9) 61.9 (22.7) 0.0047 0.097 0.0029 0.024
Highest bilirubin, mmol/l 1 (1.1) 1.7 (2.5) 2.1 (1.9) 0.0015 0.024 0.00044 0.074
Highest lactate, mmol/l 3.2 (3.2) 3.9 (2.3) 7.3 (6.1) ,0.0001 0.0024 ,0.0001 0.0042
Norepinephrine, n(%) 27 (57.4) 50 (67.6) 47 (87) 0.0026 0.33 0.0013 0.012
Dobutamine, n(%) 8 (17) 13 (17.6) 20 (37) 0.021 1 0.028 0.015
Epinephrine, n(%) 9 (19.1) 13 (17.6) 18 (33.3) 0.1
Dopamine, n(%) 3 (6.4) 6 (8.1) 5 (9.3) 0.94
HC, n(%) 24 (51.1) 38 (51.4) 44 (81.5) 0.00059 1 0.0014 0.0007
APC, n(%) 0 (0) 3 (4.1) 10 (18.5) 0.00063 0.28 0.0015 0.015
Insulin, n(%) 33 (70.2) 53 (71.6) 36 (72) 1
p; comparison between the 3 groups, no AKI, mild AKI and severe AKI. When significant p1, comparison between no AKI and mild AKI, p2, between no AKI and severe
AKI, p3, between mild AKI and severe AKI with a Mann-Whitney –test or Chi2-test. MAP: mean arterial pressure. PT: prothombin time. Hydrocortisone: HC, activated
protein C: APC. Results are expressed in median (IQR).
doi:10.1371/journal.pone.0035838.t003
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associated.
Relation between AKI and Inflammatory Parameters
(Table 4 and Figure 3)
Compared to patients with "no AKI", "mild AKI" had only IL-
6 level that reached the significance (p=0.02). During the first
48 hrs, the highest levels and the trend in "severe AKI" were
significantly different than in "no AKI" for IL-6 (p,0.0001), IL-10
(p,0.0001) and MIF (p=0.0029). Such a difference was observed
between "mild AKI" and "severe AKI" for all the measured
cytokines (Table 4). Monocyte surface HLADR expression was
low compared to healthy volunteers values [9] and did not differ
between groups (mild and severe AKI and no AKI) and overtime
(Table 4). Using a logistic regression model to explain the
relationship between inflammatory pattern and the occurrence of
"severe AKI", IL-10 and MIF were found to be independently
associated but not IL-6 and HLA-DR (data not shown).
Relation between AKI and HLA-DRB1 Genotype
HLA-DRB1 genotype analysis was performed in 149 patients
because of DNA degradation in 26 samples. This DNA
degradation concerned 14% of the RRT group and 17% of the
remaining patients. The frequencies of HLA-DRB1 alleles and of
the pairs of second HLA-DRB alleles are detailed in Tables S3A
and S3B. The partition of HLA-DRB1 alleles was similar in this
cohort with severe sepsis and septic shock compared to the
reference population (Table S3A) [24]. AKI within 48 hours was
not associated with a specific HLA-DRB genotype. The genotyp-
ing showing only two HLA-DRB1 alleles was more frequent in
severe AKI than in the rest of the population ((9%) and (1%)
respectively, p=0.050) (data not shown), but the sample size was
too small to draw a definitive conclusion. Considering the presence
of three or four alleles (two HLA-DRB1 and two second HLA-
DRB genes or two HLA-DRB1 and one second HLA-DRB gene),
their incidence did not differ between patients with severe AKI vs
no or mild AKI. Only in patients presenting four alleles, a trend
for a less homozygosity in severe AKI group than in "no AKI" or
"mild AKI" was found (p=0.080). In the RRT population during
the 1
st week, the incidence of 4 alleles was significantly lower than
in the group of patients not treated with RRT (p=0.004)
(Figure 4). In addition, within the 117 patients having 4 alleles,
incidence of the homozygotie seemed to be further more
protective, with a trend for a lower use of RRT in these patients
(8.1%) patients compared to heterozygous (20.6%) (p=0.070).
HLA-DRB genotype was never related to inflammatory pheno-
types (Figure S1).
Figure 2. Analysis of mortality according to AKI severity. A. Mortality curves according to AKI severity from day 2 to day 28. B. Univariate and
multivariate analysis of the association between mortality and AKI. (*) indicates results using competitive risk regression models (analyses adjusted on
SOFA-II, age, sex, diabetes and cancer) of mortality risk.
doi:10.1371/journal.pone.0035838.g002
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Statement of Key Findings
The key findings of this study on severe sepsis and septic shock
patients are: 1- a graded increase in mortality was associated with
the graded AKI severity; 2- severity of AKI did not relate to
vasopressor dependency index; 3- plasma cytokine (IL-10, IL-6,
and MIF) profiles differed according to AKI severity; 4- support by
RRT appeared related to different genotyping profile for HLA-
DRB genes, with a ‘‘protective" effect of the presence of 4 alleles
for HLA-DRB.
Comparison with Previous Studies
The incidence of AKI observed in this cohort of severe septic
patients from medical or surgical origin with a relatively
homogenous severity and time evolution for organ failures, is
similar to that reported by Bagshaw et al [25]. As previously shown
AKI was strongly and independently associated with a poor
prognosis, although the mechanism(s) remain unclear. In this study
as in previous reports [25,26], patients having early AKI had
higher severity scores and more organ failures compared to those
free of AKI. The new finding for severe AKI was the strong
association with mortality after application of the competitive risk
statistical method in comparison pooling of ‘‘no AKI’’ + ‘‘mild
AKI.’’ In addition to its early presence, AKI seemed to remain
Figure 3. Blood highest leukocytes, monocyte HLA-DR, plasma IL-6, IL-10 and MIF levels in AKI groups. No AKI (white diamond), mild
AKI (black diamond) and severe AKI (black circle) at day 0, day1 and day2. Mean and standard deviation are represented.
doi:10.1371/journal.pone.0035838.g003
Table 4. Systemic inflammatory parameters (worst values during the 48 first hours).
patients (n=176) No AKI (n=47) Mild AKI (n=75) Severe AKI (n=54) p p1 p2 p3
HLA-DR 4070 4692 4304 3806 0.57
(AB/C) (2640 to 9397) (2640 to 10769) (3271 to 84445) (2205 to 8953)
IL-10 52.7 24 44.1 141.7 ,0.0001 0.052 ,0.0001 ,0.0001
(pg/ml) (20. to 202) (11 to 55.5) (14.9 to 146.4) (76.2 to 539)
MIF 2224 1799 2088 4343 0.0029 0.72 0.0029 0.0031
(pg/ml) (1033 to 6757) (755 to 5127) (786 to 4947) (1392 to 11989)
IL-6 491 251 477 3769 ,0.0001 0.02 ,0.0001 0.002
(pg/ml) (160 to 38530) (87 to 532) (179 to 2489) (256 to 22823)
p; comparison between the 3 groups, no AKI, mild AKI and severe AKI. When significant: p1, comparison between no AKI and mild AKI, p2, between no AKI and severe
AKI, p3, between mild AKI and severe AKI with a Mann-Whitney –test or Chi2-test. Results are expressed in median (25 to 75th percentile).
doi:10.1371/journal.pone.0035838.t004
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after the first two days and a low number of patients (n=4) showed
a deteriorating AKI score after 2 days. This suggests that
occurrence of AKI and its severity are determined early during
the acute phase of severe sepsis.
Our limited understanding of pathogenesis of AKI during
severe sepsis gives priority to renal hypoperfusion and ischemia
[4,5]. Recent experimental septic or acute LPS injection
inflammatory studies suggest that: renal blood flow follows cardiac
output variations, being low with no resuscitation [27] and
maintained or high in resuscitated hyperkinetic shock [28;29];
renal biopsies performed early after death in septic shock patients
failed to observe diffuse and severe ischemic lesion such as renal
tubular acute necrosis [6]. In the present study, the VDI [20] did
not differ for no AKI, mild AKI and severe AKI groups. In
addition, in 43% of the patients, AKI preceded occurrence of
shock. Consequently, the classical view of renal hypoperfusion
during hemodynamic failure in severe sepsis or septic shock
leading to renal ischemia with, acute tubular necrosis and AKI can
be questioned and seems to have limited impact. Among the non
hemodynamic factors, systemic inflammation might induce a renal
‘‘immune toxicity’’ [30]. The early (the first 2 days) occurrence or
not of AKI with few later modifications and the association with
initial SOFA score and cytokines suggest such renal ‘‘immune
toxicity’’ during the early phase of severe sepsis, when inflamma-
tory processes are most active. Fresh renal tissue biopsies or
experimental renal microvessel studies showed acute renal
inflammation, with microvessel obstruction [31], prominent
tubular cell apoptosis [32] and renal tissue infiltration by immune
cells [6], supporting such hypothesis.
Systemic Inflammatory Phenotype
The role of systemic inflammation in renal injury was nicely
shown using a knockout mice model. Mice knock-out for TNF
receptors had a better preserved renal function after experimental
peritonitis [33]. When a wild type kidney is transplanted into these
mice, sepsis induced a severe renal injury only in this transplanted
kidney. High plasma IL-10, MIF and IL-6 levels have been
associated with severity and a poorer outcome in sepsis [34,35,36]
and were chosen for the present study. All groups had cytokine
levels higher than normal values, which concerned both pro- and
anti-inflammatory cytokines. Among the 3 groups, "severe AKI"
demonstrated a level of these cytokines higher than in "mild AKI"
during the first 48 hrs. The group "mild AKI" was nevertheless
higher for some even not all cytokines than patients with no AKI.
This group of patients seemed to attenuate inflammation more
rapidly, since cytokine levels became not different at day 1 and 2.
This suggests a continuum between inflammatory response and
severity of AKI. The logistic model confirmed the association
between IL-10 and MIF increase and severe AKI. This supports
the hypothesis of a renal "immune toxicity" for AKI, especially for
the most severe patients. The higher death rate in "mild AKI"
compared to "no AKI", despite moderate inflammatory response,
suggests a more complex factor interactions than systemic
inflammation itself. The type of the measured cytokines did not
appear to have specific patterns, although MIF remained higher
and stable in "severe AKI". Even previously proposed [37], the
mechanistic relation between systemic inflammation and renal
injury remains to be demonstrated.
In addition to mediator plasma levels, monocyte human
leukocyte antigen-DR (mHLA-DR) expression was measured as
a cellular innate functional test. mHLA-DR was rapidly and
deeply downregulated in circulating monocytes, but with no
prognosis predication as previously shown in severe sepsis and
septic shock [9,10,38,39]. This MHC class II expression protein is
of importance for kidney injury, since protein HLA-DR expression
was described to be constitutive in peritubular and glomerular
capillary endothelium in the early 1980s [12,13]. Kidney HLA-
DR protein expression during acute inflammation such as acute
rejection and glomerulonephritis [13] showed consistently an
induced expression on proximal tubular cells [12]. Similar findings
were observed after stimulation by interferon c [14]. The selective
induction of HLA-DR expression in kidney microvasculature
indicates an unusual regulation of class II that may contribute to
Figure 4. RRT requirement in the population over the first week according to the number of HLA-DRB gene alleles. Black bars in the 2
alleles group, gray bars in the 3 alleles group, white bars in the 4 alleles group.
doi:10.1371/journal.pone.0035838.g004
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the different groups of patients in this study (no, mild or severe),
there was no significant difference for downregulation of HLA-DR
expression in circulating monocytes, but with no information on
kidney HLA-DR expression.
Genotyping of HLA-DRB1
MHC class II and HLA alleles polymorphism have been
associated with renal diseases in diabetes type 1 nephropathy
[40,41] or anti-glomerular basement membrane disease [42]. The
critiques of these genetic studies focused on single nucleotide
polymorphism have been softened by recent Genome wide
Association Studies. These studies confirmed the association of
HLA alleles with renal diseases as HLA-DQ alpha 1 chain in
idiopathic membranous nephropathy [43], HLA-DRB1 and
HLA-DQB1 in hepatitis B virus induced nephropathy [44],
HLA-DQ and HLA-B in IgA nephropathy [45]. Altogether, these
data suggest interactions between MHC class II proteins and
glomerular components even when the underlying mechanism
remains unknown. In our knowledge, no previous study has
reported MHC class II genotyping in severe sepsis and septic
shock with AKI severity grading. Although our sample size was
relatively small, the result suggests that haplotype of HLA-DRB
containing more than two genes (i.e three or four) was protective
from AKI. The incidence of the haplotype with four genes was
significantly lower in patients requiring RRT (severe AKI) than
those treated without RRT. Four homozygote HLA-DRB genes
seemed even more protective, since the incidence of RRT tended
to be less than in heterozygotes. Although the partition of different
pattern for HLA-DRB genes did not differ in this septic population
from healthy population, these genotyping data identifies a new
genetic risk factor for severe AKI. Considering these aspects,
homozygosity might be seen as attenuating the initial immune
response and the subsequent inflammatory cascade potentially at
the kidney tissue level. The present genetic method used for
genotyping screened haplotypes and not SNPs only. The
differences were present for associated genes having linkage
disequilibrium and not for alleles only. This may account for
previous failure to show any relation between clinical phenotype
and SNPs for this highly polymorphic system.
Limitations
The findings of this study have to be carefully looked since the
sample size was relatively small to draw definitive conclusions.
These results have to be confirmed prospectively in a large
population. Another limit came from the sepsis timing of
evolution, since only the presence of organ failure started to
process for enrolment. This implies potential heterogeneity for
time evolution between patients and groups. However, the
negligible proportion of patients starting AKI after 48 hrs
attenuates such limitation.
Conclusions
This study suggests that AKI severity may reflect the intensity of
inflammatory events related to sepsis with particular impact on
tissue injury such as the kidney. This signal for inflammation and
outcome concern both mild and severe AKI. Inflammatory
phenotype and HLA-DRB genotype findings support the concept
of inflammation induced severe renal dysfunction with a certain
impact of HLA-DRB haplotypes for the most severe AKI
requiring RRT. The association between HLA genotype and
septic AKI has to be confirmed in larger population, for which
Genome Wide Associations method could be applied to evaluate
the highly polymorphic MHC class II system and to putative new
haplotypes associated with kidney injury.
Supporting Information
Figure S1 Inflammatory patterns in relation with HLA-
DRB genotype. Since HLA-DRB haplotypes are different
between AKI requiring RRT compared who did not required
RRT, we investigated the inflammatory patterns according to
haplotypes. No difference was found for monocyte HLA-DR
downregulated expression nadir and recovery trend. Similar
comparison was made for plasma IL-6, IL-10 and MIF. Blue line
corresponded to 4 genes for HLA-DRB; black line corresponded
to 2 or 3 genes for HLA-DRB.
(DOC)
Table S1 Concordance between AKIN and SOFAkidney
[1,2]. 1. de Mendonca A, Vincent JL, Suter PM, Moreno R,
Dearden NM, et al. (2000) Acute renal failure in the ICU: risk
factors and outcome evaluated by the SOFA score. Intensive Care
Med 26: 915–921. 2. Brochard L, Abroug F, Brenner M, Broccard
AF, Danner RL, et al. (2010) An Official ATS/ERS/ESICM/
SCCM/SRLF Statement: Prevention and Management of Acute
Renal Failure in the ICU Patient: an international consensus
conference in intensive care medicine. Am J Respir Crit Care Med
181: 1128–1155.
(DOC)
Table S2 Shows the use of vasopressor and the value of
vasopressor dependency index VDI according to kidney
injury severity (no, mild, severe AKI) in 146 patients
with septic shock [3]. The dose of vasoactive/vasopressor
agents is expressed as the inotropic score, a dimensionless variable
calculated as: (dopamine dose61)+(dobutamine dose61)+(adrena-
line dose6100) _ +(noradrenaline dose6100)+(phenylephrine
dose6100), wherein all doses are expressed as mg/kg/min. 3.
Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, et al.
(2009) Early use of polymyxin B hemoperfusion in abdominal
septic shock: the EUPHAS randomized controlled trial. Jama 301:
2445–2452.
(DOC)
Table S3 Shows in part A: the comparison of HLA-DRB1
allele frequencies between severe sepsis and healthy
controls; in part B: the comparison of HLA DRB gene
frequencies in the severe sepsis and healthy controls.
Interestingly, regarding the second HLA-DRB genes, the B3/B3
genotype was significantly more common in septic patients than in
reference population (24% versus 10%, p=0.01).
(DOC)
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